Non–adjuvant polichemotherapy for advanced ovarian cancer

   Aim. To evaluate the effectiveness of non-adjuvant polichemotherapy in the combined treatment of advanced ovarian cancer.   Material and methods. The material for the study was the clinical data of the 238 patients who were examined and treated in the SI “Republic Oncology scientific center” of the MHSP of the RT with morphologically proved diagnosis of ovarian cancer. The average age of patients was 45,7 ± 0,92 years. Non-adjuvant polichemotherapy was performed in 64(27,9 %) patients: 61 patients with stage III and 3 patients with stage IV of the diseases. Perfomance status of patient was evaluated by EGOG scale (WHO). The effectiveness of non-adjuvant polichemotherapy to evaluate by clinical data (scale Registry for evaluate the effectiveness of the therapy solid tumors on 4 categories, recommended by EORTC&NCL,2000y. (data of recto-vaginal bimanual observation, ultrasound and markers of tumor until treatment and after 2 cycle of the polichemotherapy). Statistical methods included program SPSS 16.0   Results and discussion. As a result of non-adjuvant polichemotherapy, complete tumor regression was noted in 16(25 %) patients, portial tumor regression was noted in 20 (31,2 %) patients, stabilization was noted in 18(28,1 %) and progression was noted in 10 (15,6 %) patients. The overall objective effectiveness of non-adjuvant polichemotherapy was equal to 84,4 %.   Conclusion. The overall objective effectiveness of non-adjuvant polichemotherapy was equal to 84,4 % and allowed the achievement of optimal surgery of 43,7 % patients. Disruption of the rhythm of chemotherapy treatment contributes to the decrease in frequency of optimal cytoreductive operations and affects the outcome of the disease.